rechnete bitte mal jemdand mit einblick gegen: wieviel wäre bei 3,1 der covid beitrag?
Albert Bourla
Look, clearly, it’s complicated and clearly, there are a lot of dynamics that are happening right now. So, when you provide guidance, which is expected in the last quarter earnings somewhere, I think at the end of January, in few weeks, we will try to separate it. So still I think we will treat COVID as a separate from base business, although there are more and more indications that we should start seeing as part of the core business given that so far, but still we were treated separately. So, we will provide details about COVID vaccine and the rest of the business into separate margins and to separate good contributions I mean and profits, but people will have to wait until we do that. Right now, I do think that the all inclusive, the 2021, we see an EPS around from $3 to $3.1 per share. Of course, as I said this is dynamic situation. This is only for the new Pfizer, because I have seen that they forgot to remove from expectations. The Abidjan contracture is completely out, that includes COVID and that could change of course, but right now, because of the dynamics, but right now I just wanted to give you a preview of how we feel things are looking.
Chris Schott
Sure. And that $3 to $3.10 number that’s reflecting this kind of expanded 2 billion doses or so of the COVID vaccine, is that – there is a lot of moving parts obviously in the number, but…
Albert Bourla
I don’t think that the expansion is what it was a moving parts let me put it this way. So wait until we give lot of specifics into it, so a little bit of patience already, I did something that’s very, very good.